Dave Fornell, DAIC Editor

Dave Fornell, Editor DAIC

Blog | Dave Fornell, DAIC Editor | January 21, 2015

Key Late-breaking Trials to Watch at ACC.15

The America College of Cardiology has released its list of key late-breaking clinical trials at the ACC 2015 meeting in March. Here are my top picks for cardiovascular device technology I am looking forward to hearing data on: 

1. Perhaps the key trial at ACC will be data from the large BEST study, which compares the Xience V drug-eluting stent (DES) to coronary bypass grft (CABG) surgery in patients with multivessel disease. It is a follow up to the SYNTAX trial, which fell short in showing the Taxus DES (at the time the top-performing stent) had long-term durability compared to CABG. However, Abbott's Xience second-generation DES beat out Taxus in the SPRIRT IV trial a couple years ago. Intervascular imaging and FFR today also see more expanded use, which combined with an improved stent platform, is expected to tip the scale in favor of stenting. 

2. More data will be presented, likely further supporting the use of transcatheter aortic valve replacement (TAVR). This includes long-term outcomes from the Edwards Sapien and Medtronic Corevalve trials, and first experience with use of a TAVR embolic protection system. The most important of the trial presentations might be data from an all-comers trial of TAVR verses surgery. This data could help open the flood gates for TAVR as a standard therapy to replace open heart procedures.
 
3. Use of CT angiography to evaluate patients presenting with chest pain to reduce costs. There a a few CTA trials being presented, which I suspect will add more evidence that CTA can be used as a primary rule-out test to help eliminate series blood testing, nuclear scans, stress tests and diagnostic angiograms.
 
4. Denervation to treat pulmonary hypertension. Renal denervation trials have had very mixed results, but experts still say the denervation may hold promise for other therapeutic areas such as this one.
 
5. Initial experience and outcomes with the MitraClip mital valve leaflet repair system. I believe this is just the beginning of a whole new segment of interventional mitral valve repair therapies that will eventually replace open heart mitral procedures.
 
6. There are two trials comparing transradial access, which is a growing trend in the United States to help lower access site complications. One will compare transradial to transfemoral access sites, and another radial verses ulnar access. 
 
See the complete list of late breaking trials, presentation locations and times. 

Below is a preview of some technologies being shown on the expo floor.

 

Related Content

News | Heart Failure

May 26, 2022 — Axon Therapies, a private company focused on addressing a root cause of heart failure, today announced ...

Home May 26, 2022
Home
News | Heart Failure

May 25, 2022 — Immune response and the lymphatic system are central to cardiac repair after a heart attack, according to ...

Home May 25, 2022
Home
News | Heart Failure

May 23, 2022 — Insights from a National Inpatient Sample Database examining race and the rates of cardiac ...

Home May 23, 2022
Home
News | Heart Failure

May 20, 2022 — Results from early clinical evaluation of the Alleviant System to treat heart failure patients with ...

Home May 20, 2022
Home
News | Heart Failure

May 19, 2022 — Cardionomic, Inc., a Minneapolis medical device company, is pleased to announce initial enrollment in ...

Home May 19, 2022
Home
News | Heart Failure

May 16, 2022 — The Agency for Science, Technology and Research’s (A*STAR) Genome Institute of Singapore (GIS) and ...

Home May 16, 2022
Home
News | Heart Failure

May 16, 2022 — Right heart failure (RHF) continues to be a major source of morbidity and mortality following left ...

Home May 16, 2022
Home
News | Heart Failure

May 5, 2022 – Cardiovascular disease is a group of conditions that can arise from a lack of physical activity, poor diet ...

Home May 05, 2022
Home
Feature | Heart Failure | By Jean-Luc Boulnois, Ph.D.

The current standard of care for heart failure (HF) is guideline-directed medical therapy combined with device-based ...

Home May 04, 2022
Home
News | Heart Failure
April 27, 2022 – The contractile and elastic properties of the heart are finely tuned. This is a prerequisite for the ...
Home April 27, 2022
Home
Subscribe Now